Skip to main content

Table 1 Input parameters used in the model and their sampling distribution for the probabilistic sensitivity analysis

From: Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines

ParameterMean (SE)DistributionSource
Clinical Parameters
Baseline Transitional Probabilities
  DFS ➔ CHF0.0053 (0.0024)BetaBuendia et al., 2013 [31]
  DFS ➔ Recurrence0.0294 (0.0029)Beta
  DFS ➔ Metastasis0.0785 (0.0140)Beta
  DFS ➔ Death0.0020 (0.0001)Beta
  CHF ➔ Recurrence0.0294 (0.0029)Beta
  CHF ➔ Metastasis0.0785 (0.0140)Beta
  CHF ➔ Death0.1500 (0.0153)BetaDokainish et al., 2017 [52]
  Recurrence ➔ Metastasis0.0785 (0.0140)BetaBuendia et al., 2013 [31]
  Recurrence ➔ Death0.2950 (0.2066)Beta
  Metastasis ➔ Death0. 0.2950 (0.2066)Beta
Relative treatment efficacy of adjuvant trastuzumab therapy
  Pooled hazard ratio for DFS0.65 (0.0825)Log-NormalGenuino et al., 2019 [40]
  Pooled hazard ratio for OS0.67 (0.0493)Log-Normal
  Pooled risk ratio for CHF3.97 (0.2240)Log-Normal
Epidemiological Data
  5 – year prevalence of Breast Cancer in the Philippines64,046 prevalent casesWHO GLOBOCAN, 2012 [8]
  Incidence of Breast Cancer in the Philippines21,057 new casesEstimated based on the 2015 new cases (Philippine Cancer Facts and Estimates, 2015 [2]) adjusted to 2017 values by applying the incidence rate calculated using the total population for 2015 [53] and 2017 [54]
  Percentage of HER2-positivity of breast cancer in the Philippines23.17%DOH Breast Cancer and Control Program, 2013 [7]
  Estimated percentage of early-stage HER2-positive breast cancer cases in the Philippines80%DOH Breast Cancer and Control Program, 2013 [7]
Cost Parameters
 DMC of adjuvant trastuzumab therapy for the intervention cohort (per patient per treatment course) – Drugs, CT administration, cardiac function assessmentPHP 1076607 (54929)GammaDOH Philippines -Pharmaceutical Division, 2018 [47]
Philippine Health Insurance Corporation, 2013 [44]
 DMC of adjuvant CT for the control cohort (per patient per treatment course) – Drugs, CT administration, cardiac function assessmentPHP 194900
(9944)
Gamma
 DNMC of adjuvant treatment for intervention cohortPHP 9432
(481)
GammaRiewpaiboon, 2014 [49]
 DNMC adjuvant treatment for control cohortPHP 3494
(178)
Gamma
 DMC at DFS state - imaging, labs, visits/consultationPHP 9493
(484)
GammaWong, 2018 [45]
 DNMC at DFS statePHP 1747
(80)
GammaRiewpaiboon, 2014 [49]
 DMC at CHF state
-hospital admission, echocardiography, drugs, cardiac monitoring
PHP 3400
(1602)
GammaPhilippine Health Insurance Corporation, 2013 [44]
 DNMC at CHF statePHP 1049 [48]GammaRiewpaiboon, 2014 [49]
 DMC at Local Recurrence state (first year) – work-up, radiotherapy, CT drugs, CT administrationPHP 567156
(3061)
GammaDOH Philippines, 2018 [46]
Philippine Health Insurance Corporation, 2013 [44]
 DNMC at Local Recurrence state (first year)PHP 8166
(1488)
GammaRiewpaiboon, 2014 [49]
 DMC at Local Recurrence state (after first year) - CT drugs, CT administrationPHP 182437
(15513)
GammaDOH Philippines, 2018 [46]
Philippine Health Insurance Corporation, 2013 [44]
 DNMC at Local Recurrence state (after first year)PHP 17817
(178)
GammaRiewpaiboon, 2014 [49]
 DMC at Local Recurrence state (after first year) – CT drugs and administrationPHP 516904
(26373)
GammaDOH Philippines, 2018 [46]
Philippine Health Insurance Corporation, 2013 [44]
 DNMC at Local Recurrence state (after first year)PHP 5939
(273)
GammaRiewpaiboon, 2014 [49]
 DMC at Distant Metastasis state (first year) - work-up, radiotherapy, CT drugs, CT administration, palliative care drugsPHP 956172
(48784)
GammaDOH Philippines, 2018 [46]
Philippine Health Insurance Corporation, 2013 [44]
 DNMC at Distant Metastasis state (first year)PHP 10131
(465)
GammaRiewpaiboon, 2014 [49]
 DMC at Distant Metastasis state (after first year) – CT drugs and administration, palliative care drugsPHP 1666816 (59531)GammaDOH Philippines, 2018 [46]
Philippine Health Insurance Corporation, 2013 [44]
 DNMC at Distant Metastasis state (after first year)PHP 5939
(273)
GammaRiewpaiboon, 2014 [49]
Utility Parameters
 DFS0.8320 (0.0084)BetaAhn et al., 2014 [41]
 CHF0.6700 (272.71)Beta
 Recurrence0.8280 (0.0262)Beta
 Metastasis0.7620 (0.0262)Beta